This database contains 202 studies, archived under the term: "drug effects"
Click here to filter this large number of results.
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study
Gareri, Pietro,
Putignano, Daria,
Castagna, Alberto,
Cotroneo, Antonino Maria,
De Palo, Grazia,
Fabbo, Andrea,
Forgione, Luigi,
Giacummo, Attilio,
Lacava, Roberto,
Marino, Saverio,
Simone, Maurizio,
Zurlo, Amedeo,
Putignano, Salvatore
Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]
A phase 3 trial of semagacestat for treatment of Alzheimer’s disease
Doody, Rachelle S.,
Raman, Rema,
Farlow, Martin,
Iwatsubo, Takeshi,
Vellas, Bruno,
Joffe, Steven,
Kieburtz, Karl,
He, Feng,
Sun, Xiaoying,
Thomas, Ronald G.,
Aisen, Paul S,
Siemers, Eric,
Sethuraman, Gopalan,
Mohs, Richard
Background: Alzheimer’s disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer’s disease.; Methods: We conducted a double-blind, placebo-controlled trial in which 1537 patients […]
The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study
de Waal, Hanneke,
Stam, Cornelis J.,
Lansbergen, Marieke M.,
Wieggers, Rico L.,
Kamphuis, Patrick J. G. H.,
Scheltens, Philip,
Maestú, Fernando,
van Straaten, Elisabeth C. W.
Background: Synaptic loss is a major hallmark of Alzheimer’s disease (AD). Disturbed organisation of large-scale functional brain networks in AD might reflect synaptic loss and disrupted neuronal communication. The medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect, is designed to enhance synapse formation and function and has been shown to improve memory performance […]
Continuous use of antipsychotics and its association with mortality and hospitalization in institutionalized Chinese older adults: an 18-month prospective cohort study
Chan, Tuen-Ching,
Luk, James Ka-Hay,
Shea, Yat-Fung,
Lau, Ka-Hin,
Chan, Felix Hon-Wai,
Yu, Gabriel Ka-Kui,
Chu, Leung-Wing
Background: Previous meta-analyses have suggested that antipsychotics are associated with increased mortality in dementia patients with behavioral and psychological symptoms (BPSD). Subsequent observational studies, however, have produced conflicting results. In view of this controversy and the lack of any suitable pharmacological alternative for BPSD, this study aimed to investigate the relationship between continuous use of […]
Results of the citalopram to enhance cognition in Huntington disease trial
Beglinger, Leigh J.,
Adams, William H.,
Langbehn, Douglas,
Fiedorowicz, Jess G.,
Jorge, Ricardo,
Biglan, Kevin,
Caviness, John,
Olson, Blair,
Robinson, Robert G.,
Kieburtz, Karl,
Paulsen, Jane S.
Background: The objective of this study was to evaluate citalopram for executive functioning in Huntington’s disease (HD).; Methods: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and […]
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies
Anderson, Craig,
Teo, Koon,
Gao, Peggy,
Arima, Hisatomi,
Dans, Antonio,
Unger, Thomas,
Commerford, Patrick,
Dyal, Leanne,
Schumacher, Helmut,
Pogue, Janice,
Paolasso, Ernesto,
Holwerda, Nicolaas,
Chazova, Irina,
Binbrek, Azan,
Young, James,
Yusuf, Salim
Background: cardiovascular risk factors are associated with dementia and cognitive decline. We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials.; Methods: in the main study, ONTARGET, a double-blind, double-dummy, randomised controlled trial, […]
Lipid lowering agents, cognitive decline, and dementia: the three-city study
Ancelin, Marie-Laure,
Carrière, Isabelle,
Barberger-Gateau, Pascale,
Auriacombe, Sophie,
Rouaud, Olivier,
Fourlanos, Spiros,
Berr, Claudine,
Dupuy, Anne-Marie,
Ritchie, Karen
The aim of this prospective cohort study was to evaluate the effects of lipid lowering agent (LLA) intake on cognitive function in 6,830 community-dwelling elderly persons. Cognitive performance (global cognitive functioning, visual memory, verbal fluency, psychomotor speed, and executive function), clinical diagnosis of dementia, and fibrate and statin use, were evaluated at baseline, and 2, […]